Use and Spending for Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries

Publisher： John Wiley & Sons Inc

E-ISSN： 2151-4658|67|9|1210-1218

ISSN： 2151-464x

Source： ARTHRITIS CARE AND RESEARCH, Vol.67, Iss.9, 2015-09, pp. : 1210-1218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis

By Turkstra E.   Ng S.-K.   Scuffham P.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 10, 2011-10 ,pp. : 1885-1897

Informa Healthcare

Access to resources Recommend Favorite

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

By Kielhorn Adrian   Porter Duncan   Diamantopoulos Alexander   Lewis Gavin  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2639-2650

Informa Healthcare

Access to resources Recommend Favorite

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1671-1678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: Inflammation, Disease‐Modifying Antirheumatic Drugs, Lipids, and Cardiovascular Risk in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 2, 2015-02 ,pp. : 327-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 12, 2015-12 ,pp. : 1266-1273

John Wiley & Sons Inc

Access to resources Recommend Favorite